Published in Prostaglandins on November 01, 1976
Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br J Pharmacol (1982) 2.01
Thromboxane generation by human peripheral blood polymorphonuclear leukocytes. J Exp Med (1978) 1.57
Thromboxane A2 mediates augmented polymorphonuclear leukocyte adhesiveness. J Clin Invest (1980) 1.48
Release of leukotriene B4 from human neutrophils and its relationship to degranulation induced by N-formyl-methionyl-leucyl-phenylalanine, serum-treated zymosan and the ionophore A23187. Immunology (1983) 1.30
The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol (1983) 1.17
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
A possible role of arachidonic acid in human neutrophil aggregation and degranulation. Am J Pathol (1979) 1.06
Peripheral analgesia: mechanism of the analgesic action of aspirin-like drugs and opiate-antagonists. Br J Clin Pharmacol (1980) 0.98
Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med (1981) 0.97
A comparison of air pouch, sponge and pleurisy models of acute carrageenan inflammation in the rat. Agents Actions (1986) 0.84
Human recombinant IL-1 receptor antagonist (IL-1Ra) inhibits leukotriene B4 generation from human monocyte suspensions stimulated by lipopolysaccharide (LPS). Clin Exp Immunol (1993) 0.82
Platelet-leukocyte interaction: activation of rabbit platelets by FMLP-stimulated neutrophils. Br J Pharmacol (1987) 0.82
Prostaglandin biosynthesis in pulmonary macrophages. Am J Pathol (1979) 0.81
The release of thromboxane B2 by rabbit peritoneal polymorphonuclear leucocytes [proceedings]. Br J Pharmacol (1978) 0.78
Prostaglandin endoperoxides and thromboxanes: formation and effects. Naunyn Schmiedebergs Arch Pharmacol (1977) 0.77
Introduction: thromboxane in biological systems and the possible impact of its inhibition. Br J Clin Pharmacol (1983) 0.76
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Prostaglandins released by the spleen. Nature (1968) 7.61
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A (1986) 3.78
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
A chemotactic role for prostaglandins released from polymorphonuclear leucocytes during phagocytosis. Br J Pharmacol (1975) 2.79
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br J Pharmacol (1989) 2.68
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins (1980) 2.59
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
Proceedings: Prostaglandin production by rabbit peritoneal polymorphonuclear leukocytes in vitro. Br J Pharmacol (1972) 2.53
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51